drugset
drugset / Trial / NCT05653453

Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer

NCT05653453 ↗

Phase 3 Recruiting 512 enrolled Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

The Objectives of this clinical trial is to evaluate the efficacy and safety of tumor treating fields combined with gemcitabine and albumin bound paclitaxel in the treatment of locally advanced pancreatic cancer.

Timeline

Start
2022-12-20
Primary completion
2026-12-25
Completion
2027-09-28

Drugs

EvaluationDrugModalityDoseRoute
Background Gemcitabine Small molecule 1000 mg/m2 —
Background albumin binding paclitaxel Unknown 125 mg/m2 Intravenous

Indications

pancreatic neoplasm